Advaxis to Present at the BIO International Convention

Before you go, we thought you'd like these...
Before you go close icon

Advaxis to Present at the BIO International Convention

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS) ("Advaxis" or the "Company"), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Daniel J. O'Connor, Senior VP, Chief Legal, and Business Development Officer at Advaxis, will present at the BIO International Convention (BIO 2013) on April 22 at 3:00 p.m. at the McCormick Place Convention Center in Chicago, IL. Mr. O'Connor will provide a review of the progress of the Company's lead drug candidate, ADXS-HPV. Updated data regarding ADXS-HPV will be disclosed at the 2013 American Society of Clinical Oncology Annual Meeting in June.

The Convention is the largest global event for biotechnology and pharmaceutical industries that attract many of the biggest names across all major continents. BIO 2013 will provide key networking and partnering opportunities, as well as generate insights and inspirations on current trends that are essential in the development of innovative and better technologies for the future.


About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.

ADXS-HPV is currently being evaluated in 5 clinical trials for human papillomavirus, or HPV, associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), CIN 2/3 (U.S. study, Clinical Trials.gov Identifier NCT01116245), head & neckcancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trial.gov Identifier NCT01671488). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research - UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

For more information please visit: advaxis.com|Facebook | twitter | LinkedIn

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies, statements regarding ADXS-HPV, its clinical stage product candidate, and immunotherapies, and their effect on cancer, as well as statements as to the development of new constructs.Such forward-looking statements are subject to a number of risks and uncertainties, such as those described in the "Risk Factors" section in Advaxis' Annual Report on Form 10-K for the fiscal year ended October 31, 2012, which is available atwww.sec.gov , as well as its other filings with the Securities and Exchange Commission.Advaxis undertakes no obligation to revise these forward-looking statements to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.



Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
ir@advaxis.com

KEYWORDS:   United States  North America  Illinois  New Jersey

INDUSTRY KEYWORDS:

The article Advaxis to Present at the BIO International Convention originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners